Mgr. Lukáš Sourada
Ph.D. Student
Laboratory Oncology Translational Research
Our team investigates fundamental mechanisms and translates findings from bench to bedside, combining preclinical models with clinical insight.
Researcher at ICRC with focus on translational medicine. Combines preclinical insights with clinical practice across cardiology, neurology, and oncology programs.
Currently leads / contributes to interdisciplinary projects bridging molecular biology, imaging, and patient care at St. Anne's University Hospital Brno.
Research Group
- Team size
- Team size: 18 Researchers
- Place
- Place: Building C2, 2nd Floor
- Collaborates with
- Collaborates with Charles University, Prague
Head of Research Group
- doc. RNDr. Jan Škoda, Ph.D.
Members
Mgr. Veronika Knechtová
Ph.D. Student
Mgr. Adna Goralija
Ph.D. Student
Mgr. Adéla Kubištová
Ph.D. Student
Mgr. Hana Suchánková
Ph.D. Student
Bc. Běla Stejskalová
Research Assistant
Dagmar Štodtová
Research Technician
RNDr. Petra Čermáková, Ph.D.
Postdoctoral Researcher
doc. Mgr. Tomáš Bárta, Ph.D.
Senior Postdoctoral Researcher
Petr Těšina, Ph.D.
Senior Postdoctoral Researcher
Mgr. Peter Fabian, Ph.D.
Senior Postdoctoral Researcher
Mgr. Blanka Jančeková, Ph.D.
Lab Manager
Mgr. Mária Krchniaková, Ph.D.
Lab Manager, Research Specialist
Mgr. Ondřej Zapletal, Ph.D.
Lab Technician
RNDr. Petr Chlapek, Ph.D., DiS.
Senior Research Specialist
doc. RNDr. Jakub Neradil, Ph.D.
Senior Research Specialist
Iryna Horak, Ph.D.
Research Specialist
doc. RNDr. Jan Škoda, Ph.D.
Senior Research Team Leader
Team Assistant
Mgr. Blanka Jančeková, Ph.D.
Administrative Support
Main Objectives
- Identification of activated RTK and downstream signaling pathways as druggable molecular targets in relapsed / refractory pediatric solid tumors and giant cell tumor of bone.
- Analysis of the expression of key stemness factors and p53 family proteins in relation to the tumorigenicity of sarcoma cells.
- Deciphering the role of mitochondrial dynamics and autophagy in acquisition of stemness using clinically relevant models of resistance development in pediatric solid tumors.
Research focus
Laboratory translational research – with main focus on pediatric oncology – in close cooperation with clinicians and pathologists represents an important approach bringing new information concerning tumor biology from bench to bedside. This strategy encompasses especially the identification of activated signaling molecules within tumors that can be targeted by specific low-molecular-weight inhibitors.
Research of cancer stem cell phenotype in relation to the tumorigenicity and resistance to the conventional therapy.
Main partners: Michael Hogarty (Children’s Hospital of Philadelphia, PA, USA; Dr. Lucília Saraiva (University of Porto, Portugalsko); Dr. Patric Jan Jansson (University of Sydney, Austrálie); Prof. Dr. Igor Adameyko (Karolinska Institutet, Stockholm, Švédsko / Medical University of Vienna, Rakousko)
Technological equipment
- Cell Culture Unit (BSL-2 level) for primary cultures and established cell lines including GMOs
- Microscopy Unit for immunofluorescence imaging and image analyses
- 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA)
- Azure 600 Western Blot Imaging System (Azure Biosystems, Dublin, CA, USA)
- CytoFLEX S flow cytometer (Beckman Coulter, Indianapolis, IN, USA)
- IncuCyte SX1 live-cell imaging system (Sartorius, Goettingen, Germany)
Selected Results
- Kameneva P, Melnikova VI, Kastriti ME, Kurtova A, Kryukov E, Murtazina A, Faure L, Poverennaya I, Artemov AV, Kalinina TS, Kudryashov NV, Bader M, Skoda J, Chlapek P, Curylova L, Sourada L, Neradil J, Tesarova M, Pasqualetti M, Gaspar P, Yakushov VD, Sheftel BI, Zikmund T, Kaiser J, Fried K, Alenina N, Voronezhskaya EE, Adameyko I. Serotonin limits generation of chromaffin cells during adrenal organ development. Nat Commun. 2022, 13(1):2901.
- Çoku J, Booth DM, Skoda J, Pedrotty MC, Vogel J, Liu K, Vu A, Carpenter EL, Ye JC, Chen MA, Dunbar P, Scadden E, Yun TD, Nakamaru-Ogiso E, Area-Gomez E, Li Y, Goldsmith KC, Reynolds CP, Hajnoczky G, Hogarty MD. Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. EMBO J. 2022, 41:e108272.
- Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacol Res. 2019, 139:298-313.
- Curylova L, Ramos H, Saraiva L, Skoda J. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. Cancer Letters. 2022, 525:131-145.
- Skoda J, Neradil J, Staniczkova Zambo I, Nunukova A, Macsek P, Borankova K, Dobrotkova V, Nemec P, Sterba J, Veselska R. Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial /Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells. Cancers. 2020, 12(1):196.
- Paukovcekova S, Skoda J, Neradil J, Mikulenkova E, Chlapek P, Sterba J, Richardson DR, Veselska R. Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms. Cancers. 2020, 12(12):3781.
- Macsek P, Skoda J, Krchniakova M, Neradil J, Veselska R. Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma. Int J Mol Sci. 2021, 23(1):376.
- Mahdal M, Neradil J, Mudry P, Paukovcekova S, Staniczkova Zambo I, Urban J, Macsek P, Pazourek L, Tomas T, Veselska R. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling. Cancers. 2021, 13(14):3543.
